Literature DB >> 22544171

Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: adipose depot specificity and gender dimorphism.

Assim A Alfadda1, Reem M Sallam, Muhammad Azhar Chishti, Amr S Moustafa, Sumbul Fatma, Waleed S Alomaim, Mohammed Y Al-Naami, Abdulelah F Bassas, George P Chrousos, Hyunsun Jo.   

Abstract

Chemerin, a recognized chemoattractant, is expressed in adipose tissue and plays a role in adipocytes differentiation and metabolism. Gender- and adipose tissue-specific differences in human chemerin expression have not been well characterized. Therefore, these differences were assessed in the present study. The body mass index (BMI) and the circulating levels of chemerin and other inflammatory, adiposity and insulin resistance markers were assessed in female and male adults of varying degree of obesity. Chemerin mRNA expression was also measured in paired subcutaneous and visceral adipose tissue samples obtained from a subset of the study subjects. Serum chemerin concentrations correlated positively with BMI and serum leptin levels and negatively with high density lipoprotein (HDL)-cholesterol levels. No correlation was found between serum chemerin concentrations and fasting glucose, total cholesterol, low density lipoprotein (LDL)-cholesterol, triglycerides, insulin, C-reactive protein or adiponectin. Similarly, no relation was observed with the homeostasis model assessment for insulin resistance (HOMA-IR) values. Gender- and adipose tissue-specific differences were observed in chemerin mRNA expression levels, with expression significantly higher in women than men and in subcutaneous than visceral adipose tissue. Interestingly, we found a significant negative correlation between circulating chemerin levels and chemerin mRNA expression in subcutaneous fat. Among the subjects studied, circulating chemerin levels were associated with obesity markers but not with markers of insulin resistance. At the tissue level, fat depot-specific differential regulation of chemerin mRNA expression might contribute to the distinctive roles of subcutaneous vs. visceral adipose tissue in human obesity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544171      PMCID: PMC3887762          DOI: 10.1007/s10059-012-0012-7

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  32 in total

1.  Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease.

Authors:  M C Alessi; F Peiretti; P Morange; M Henry; G Nalbone; I Juhan-Vague
Journal:  Diabetes       Date:  1997-05       Impact factor: 9.461

2.  Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}.

Authors:  Sebastian D Parlee; Matthew C Ernst; Shanmugam Muruganandan; Christopher J Sinal; Kerry B Goralski
Journal:  Endocrinology       Date:  2010-04-02       Impact factor: 4.736

3.  Insulin-sensitive obesity.

Authors:  Nora Klöting; Mathias Fasshauer; Arne Dietrich; Peter Kovacs; Michael R Schön; Matthias Kern; Michael Stumvoll; Matthias Blüher
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-06-22       Impact factor: 4.310

Review 4.  Chemerin: at the crossroads of inflammation and obesity.

Authors:  Matthew C Ernst; Christopher J Sinal
Journal:  Trends Endocrinol Metab       Date:  2010-11       Impact factor: 12.015

5.  Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery.

Authors:  Henrike Sell; Adeline Divoux; Christine Poitou; Arnaud Basdevant; Jean-Luc Bouillot; Pierre Bedossa; Joan Tordjman; Jürgen Eckel; Karine Clément
Journal:  J Clin Endocrinol Metab       Date:  2010-04-07       Impact factor: 5.958

6.  Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension.

Authors:  Mengliu Yang; Gangyi Yang; Jing Dong; Ying Liu; Haihong Zong; Hua Liu; Guenther Boden; Ling Li
Journal:  J Investig Med       Date:  2010-10       Impact factor: 2.895

7.  Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes.

Authors:  Katherine Samaras; Natalia K Botelho; Donald J Chisholm; Reginald V Lord
Journal:  Obesity (Silver Spring)       Date:  2009-12-17       Impact factor: 5.002

8.  Mechanisms regulating repression of haptoglobin production by peroxisome proliferator-activated receptor-gamma ligands in adipocytes.

Authors:  Cecile Vernochet; Kathryn E Davis; Philipp E Scherer; Stephen R Farmer
Journal:  Endocrinology       Date:  2009-12-01       Impact factor: 4.736

9.  Effect of bariatric surgery on circulating chemerin levels.

Authors:  C Ress; A Tschoner; J Engl; A Klaus; H Tilg; C F Ebenbichler; J R Patsch; S Kaser
Journal:  Eur J Clin Invest       Date:  2010-01-25       Impact factor: 4.686

10.  Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells.

Authors:  Henrike Sell; Jurga Laurencikiene; Annika Taube; Kristin Eckardt; Andrea Cramer; Angelika Horrighs; Peter Arner; Jürgen Eckel
Journal:  Diabetes       Date:  2009-08-31       Impact factor: 9.461

View more
  29 in total

1.  Polycystic ovary syndrome: possible involvement of androgen-induced, chemerin-mediated ovarian recruitment of monocytes/macrophages.

Authors:  Patricia D A Lima; Anne-Laure Nivet; Qi Wang; Yi-An Chen; Arthur Leader; Annie Cheung; Chii-Ruey Tzeng; Benjamin K Tsang
Journal:  Biol Reprod       Date:  2018-10-01       Impact factor: 4.285

Review 2.  Adipokines in psoriasis: An important link between skin inflammation and metabolic alterations.

Authors:  Kerstin Wolk; Robert Sabat
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

3.  Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis.

Authors:  Ya Li; Bingyin Shi; Sheli Li
Journal:  PLoS One       Date:  2014-12-03       Impact factor: 3.240

4.  Protective effect of liraglutide against ER stress in the liver of high-fat diet-induced insulin-resistant rats.

Authors:  Jing Yang; Na Ao; Jian Du; Xiaochen Wang; Yini He
Journal:  Endocrine       Date:  2014-11-25       Impact factor: 3.633

Review 5.  Mechanisms and metabolic implications of regional differences among fat depots.

Authors:  Tamara Tchkonia; Thomas Thomou; Yi Zhu; Iordanes Karagiannides; Charalabos Pothoulakis; Michael D Jensen; James L Kirkland
Journal:  Cell Metab       Date:  2013-04-11       Impact factor: 27.287

6.  The chemerin knockout rat reveals chemerin dependence in female, but not male, experimental hypertension.

Authors:  Stephanie W Watts; Emma S Darios; Adam E Mullick; Hannah Garver; Thomas L Saunders; Elizabeth D Hughes; Wanda E Filipiak; Michael G Zeidler; Nichole McMullen; Christopher J Sinal; Ramya K Kumar; David J Ferland; Gregory D Fink
Journal:  FASEB J       Date:  2018-06-15       Impact factor: 5.191

7.  The increase of serum chemerin concentration is mainly associated with the increase of body mass index in obese, non-diabetic subjects.

Authors:  T Sledzinski; J Korczynska; A Hallmann; L Kaska; M Proczko-Markuszewska; T Stefaniak; M Sledzinski; J Swierczynski
Journal:  J Endocrinol Invest       Date:  2012-11-27       Impact factor: 4.256

Review 8.  Sex dimorphism and depot differences in adipose tissue function.

Authors:  Ursula A White; Yourka D Tchoukalova
Journal:  Biochim Biophys Acta       Date:  2013-05-16

Review 9.  Chemerin as an independent predictor of cardiovascular event risk.

Authors:  Sinan İnci; Gökhan Aksan; Pınar Doğan
Journal:  Ther Adv Endocrinol Metab       Date:  2016-02-08       Impact factor: 3.565

10.  The adipokine chemerin amplifies electrical field-stimulated contraction in the isolated rat superior mesenteric artery.

Authors:  Emma S Darios; Brittany M Winner; Trevor Charvat; Antoni Krasinksi; Sreenivas Punna; Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-01       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.